Journal of Lipid Research, Vol 38, 564-575, Copyright © 1997 by Lipid Research, Inc.

ARTICLES

Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo

B Eisele, R Budzinski, P Muller, R Maier and M Mark
Department of Biology, Boehringer Ingelheim Research, Biberach, Germany.

BIBB 515 (1-(4-chlorobenzoyl)-4-((4-(2-oxazolin-2-yl) benzylidene))piperidine) is a potent and selective inhibitor of 2,3- oxidosqualene cyclase (OSC) [EC 5.4.99.7]. In rats and mice BIBB 515 inhibited OSC in vivo in a dose-dependent manner after 1, 3, and 5 h with ED50 values from 0.2 to 0.5 mg/kg (1 to 5 h) in rats and 0.36 (1 h) to 15.5 (3 h) and 33.3 (5 h) mg/kg in mice. Inhibition of [14C]acetate incorporation into sterols was found to parallel the effects on OSC when measured after 1 h (mice) or 3 h (rats). ED50 calculated were 0.9 mg/kg (mice) and 0.1 mg/kg (rats). Dose-dependent lipid-lowering activity was seen in normolipemic hamsters after 11 days treatment (-19% for total cholesterol and -32% for VLDL + LDL cholesterol at 55 mg/kg BIBB 515 per day) and in hyperlipemic hamsters after 25 days (-25% for total cholesterol and -59% for LDL-cholesterol at 148 mg/kg BIBB 515 per day). Calculation of kinetic parameters revealed no relevant differences between control and treatment groups in LDL clearance or fractional catabolic rates, but significant reductions of LDL production rates (-30% to -54%). Liver LDL receptor mRNA of the treated animals was not or only slightly increased. Liver VLDL secretion as measured by the Triton WR1339 method was reduced after BIBB 515 in rats and hamsters. It is concluded that the lipid- lowering effect of BIBB 515 is mainly the result of an inhibition of LDL production rather than due to an increase in LDL catabolism. OSC inhibitors may offer a novel approach for lipid-lowering therapy.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. Wong, C. M. Quinn, I. C. Gelissen, and A. J. Brown Endogenous 24(S),25-Epoxycholesterol Fine-tunes Acute Control of Cellular Cholesterol Homeostasis J. Biol. Chem., January 11, 2008; 283(2): 700 - 707. [Abstract] [Full Text] [PDF]

				H. Okazaki, F. Tazoe, S. Okazaki, N. Isoo, K. Tsukamoto, M. Sekiya, N. Yahagi, Y. Iizuka, K. Ohashi, T. Kitamine, et al. Increased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liver J. Lipid Res., September 1, 2006; 47(9): 1950 - 1958. [Abstract] [Full Text] [PDF]

				R. J. Cenedella, R. Jacob, D. Borchman, D. Tang, A. R. Neely, A. Samadi, R. P. Mason, and P. Sexton Direct perturbation of lens membrane structure may contribute to cataracts caused by U18666A, an oxidosqualene cyclase inhibitor J. Lipid Res., July 1, 2004; 45(7): 1232 - 1241. [Abstract] [Full Text] [PDF]

				K. Ohashi, J.-i. Osuga, R. Tozawa, T. Kitamine, H. Yagyu, M. Sekiya, S. Tomita, H. Okazaki, Y. Tamura, N. Yahagi, et al. Early Embryonic Lethality Caused by Targeted Disruption of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Gene J. Biol. Chem., October 31, 2003; 278(44): 42936 - 42941. [Abstract] [Full Text] [PDF]

				C. Taghibiglou, A. Carpentier, S. C. Van Iderstine, B. Chen, D. Rudy, A. Aiton, G. F. Lewis, and K. Adeli Mechanisms of Hepatic Very Low Density Lipoprotein Overproduction in Insulin Resistance. EVIDENCE FOR ENHANCED LIPOPROTEIN ASSEMBLY, REDUCED INTRACELLULAR ApoB DEGRADATION, AND INCREASED MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN A FRUCTOSE-FED HAMSTER MODEL J. Biol. Chem., March 17, 2000; 275(12): 8416 - 8425. [Abstract] [Full Text] [PDF]

				R.-i. Tozawa, S. Ishibashi, J.-i. Osuga, H. Yagyu, T. Oka, Z. Chen, K. Ohashi, S. Perrey, F. Shionoiri, N. Yahagi, et al. Embryonic Lethality and Defective Neural Tube Closure in Mice Lacking Squalene Synthase J. Biol. Chem., October 22, 1999; 274(43): 30843 - 30848. [Abstract] [Full Text] [PDF]

				J. Mitchell and R. J. Cenedella Human Lens Cholesterol Concentrations in Patients Who Used Lovastatin or Simvastatin Arch Ophthalmol, May 1, 1999; 117(5): 653 - 657. [Abstract] [Full Text] [PDF]